Acute Coronary Disease Background information for medical media outside the US only This selection gives an overview on background material for Acute Coronary Disease available on the Boehringer Ingelheim corporate website.

News Releases

• 27 March 2008Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission
• 25 January 2008European Medicines Agency recommends approval of novel oral anticoagulant, dabigatran etexilate (Pradaxa®)
• 17 January 2008Boehringer Ingelheim announces enrolment completion of the largest atrial fibrillation outcomes trial - The RE-LY® Study
• news release archive

Documents

• Fact sheet: Dabigatran Etexilate - A Breakthrough in Anticoagulation - March 2008 - PDF (55 KB)
• Fact sheet: Dabigatran Etexilate - March 2008 - PDF (63 KB)
• RE-VOLUTION: Thromboembolic Disease - Clinical Trials - March 2008 - PDF (1.1 MB)
• Backgrounder: Boehringer Ingelheim at a glance - March 2008 - PDF (2,2 MB)
• Backgrounder: Dabigatran Etexilate - A brief history - March 2008 - PDF (35 KB)
• Backgrounder: Venous Thromboembolism (VTE) - March 2008 - PDF (51 KB)